310
Views
0
CrossRef citations to date
0
Altmetric
Novel Vaccines

The need for development of other enterovirus vaccines in addition to EV-A71 vaccine

& ORCID Icon
Article: 2340854 | Received 27 Mar 2024, Accepted 05 Apr 2024, Published online: 23 Apr 2024

References

  • Wang Y, Feng Z, Yang Y, Self S, Gao Y, Longini IM, Wakefield J, Zhang J, Wang L, Chen X, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology. 2011;22(6):781–2. doi: 10.1097/EDE.0b013e318231d67a.
  • Zhang J, Sun J, Chang Z, Zhang W, Wang Z, Feng Z. Characterization of hand, foot, and mouth disease in China between 2008 and 2009. Biomed Environ Sci. 2011;24(3):214–21. doi: 10.3967/0895-3988.2011.03.002.
  • Lee TC, Guo HR, Su HJ, Yang YC, Chang HL, Chen KT. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J. 2009;28(10):904–10. doi: 10.1097/INF.0b013e3181a41d63.
  • Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370(9):829–37. doi: 10.1056/NEJMoa1303224.
  • Saguil A, Kane SF, Lauters R, Mercado MG. Hand-foot-and mouth disease: rapid evidence review. Am Fam Physician. 2019;100:408–14.
  • Jia J, Kong F, Xin X, Liang J, Xin H, Dong L, Jiang F. Epidemiological characteristics of hand, foot, and mouth disease outbreaks in Qingdao, 2009–2018. Iran J Public Health. 2021;50(5):999–1008. doi: 10.18502/ijph.v50i5.6117.
  • Li Y, Chang Z, Wu P, Liao Q, Liu F, Zheng Y, Luo L, Zhou Y, Chen Q, Yu S, et al. Emerging enteroviruses causing hand, foot and mouth disease, China, 2010–2016. Emerg Infect Dis. 2018;24(10):1902–6. doi: 10.3201/eid2410.171953.
  • Bian L, Wang Y, Yao X, Mao Q, Xu M, Liang Z. Coxsackievirus A6: a new emerging pathogen causing hand, foot and mouth disease outbreaks worldwide. Expert Rev Anti Infect Ther. 2015;13(9):1061–71. doi: 10.1586/14787210.2015.1058156.
  • Lu QB, Zhang XA, Wo Y, Xu HM, Li XJ, Wang XJ, Ding SJ, Chen XD, He C, Liu LJ, et al. Circulation of coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009–2011. PLoS One. 2012;7(12):e52073. doi: 10.1371/journal.pone.0052073.
  • Liao Y, Jiang Q, Huo X, Yu L, Yang J, Zhao H, Li D, Xu X, Jiang G, Zhang C, et al. Preclinical safety evaluation of a bivalent inactivated EV71-CA16 vaccine in mice immunized intradermally. Hum Vaccin Immunother. 2023;19(1):2209472. doi: 10.1080/21645515.2023.2209472.
  • CDE. 2008. (China). The general principles for the technical review of pre-clinical safety evaluation of biological products for prevention.
  • Verdier F, Barrow PC, Burge J. Reproductive toxicity testing of vaccines. Toxicology. 2003;185(3):213–9. doi: 10.1016/S0300-483X(02)00611-X.
  • Lebron JA, Wolf JJ, Kaplanski CV, Ledwith BJ. Ensuring the quality, potency and safety of vaccines during preclinical development. Expert Rev Vaccines. 2005;4(6):855–66. doi: 10.1586/14760584.4.6.855.
  • Baldrick P. Dose site reactions and related findings after vaccine administration in safety studies. J Appl Toxicol. 2016;36(8):980–90. doi: 10.1002/jat.3314.